MaxCyte, Inc. Files 8-K on Financials
Ticker: MXCT · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1287098
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: MXCT
TL;DR
MaxCyte dropped an 8-K detailing its financials - check it out.
AI Summary
MaxCyte, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and headquartered in Rockville, Maryland.
Why It Matters
This filing provides investors with crucial updates on MaxCyte's financial performance and condition, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or unusual risks.
Key Players & Entities
- MAXCYTE, INC. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Rockville, Maryland (location) — Principal executive offices
- 001-40674 (other) — SEC File Number
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filed?
The filing date, and the date of the earliest event reported, is January 13, 2025.
Where is MaxCyte, Inc. headquartered?
MaxCyte, Inc.'s principal executive offices are located at 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850.
What is MaxCyte, Inc.'s SEC file number?
MaxCyte, Inc.'s SEC file number is 001-40674.
What is the SIC code for MaxCyte, Inc.?
The Standard Industrial Classification (SIC) code for MaxCyte, Inc. is 8731, which falls under SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2025-01-13 07:30:24
Key Financial Figures
- $0.01 — ge on which registered Common Stock, $0.01 par value MXCT The Nasdaq Stock Mar
Filing Documents
- mxct-20250113x8k.htm (8-K) — 37KB
- mxct-20250113xex99d1.htm (EX-99.1) — 19KB
- mxct-20250113xex99d1001.jpg (GRAPHIC) — 4KB
- 0001558370-25-000151.txt ( ) — 189KB
- mxct-20250113.xsd (EX-101.SCH) — 3KB
- mxct-20250113_lab.xml (EX-101.LAB) — 16KB
- mxct-20250113_pre.xml (EX-101.PRE) — 10KB
- mxct-20250113x8k_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 13, 2025, MaxCyte, Inc. (the "Company") issued a press release announcing preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2024. A copy of this press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated January 13, 2025 104 Cover Page Interactive Data (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MaxCyte, Inc. Dated: January 13, 2025 By: /s/ Douglas Swirsky Douglas Swirsky Chief Financial Officer